BACKGROUND: Extracorporeal lung assist has been proposed as an invasive measure in patients with acute respiratory distress syndrome (ARDS) when oxygenation is critically impaired. However, this technique generally requires high personnel and technical resources. We report on a new system, which is characterised by a short circuit arterio-venous shunt using arterio-venous pressure gradient as driving force (pumpless extracorporeal lung assist [pECLA]). PATIENTS AND METHODS: In 30 patients with ARDS due to multitrauma, pneumonia or after surgery (p(a)O(2)/F(I)O(2)-ratio 67+/-23 mmHg) pECLA was established by insertion of cannulae to the femoral artery and vein followed by connection with a membrane gas exchanger. For this system, only "low dose" continuous heparin infusion is required. RESULTS: Arterial oxygenation was acutely and significantly increased by pECLA (p(a)O(2)/F(I)O(2)=103+/-56 mmHg 2 h after begin) and carbon dioxide removal was markedly enhanced in 25 out of 30 patients (87%) allowing a lung protective ventilation strategy. The mean duration of pECLA therapy was 6.5 days, 15 patients (50%) died due to ARDS or non-ARDS related reasons. CONCLUSION: pECLA represents a feasable and effective treatment in patients with severe ARDS. Compared with pump-driven systems pECLA is characterised by low costs and reduced personnel requirements. However, mortality remains high in patients suffering from severe ARDS despite newer treatment modalities.
BACKGROUND: Extracorporeal lung assist has been proposed as an invasive measure in patients with acute respiratory distress syndrome (ARDS) when oxygenation is critically impaired. However, this technique generally requires high personnel and technical resources. We report on a new system, which is characterised by a short circuit arterio-venous shunt using arterio-venous pressure gradient as driving force (pumpless extracorporeal lung assist [pECLA]). PATIENTS AND METHODS: In 30 patients with ARDS due to multitrauma, pneumonia or after surgery (p(a)O(2)/F(I)O(2)-ratio 67+/-23 mmHg) pECLA was established by insertion of cannulae to the femoral artery and vein followed by connection with a membrane gas exchanger. For this system, only "low dose" continuous heparin infusion is required. RESULTS: Arterial oxygenation was acutely and significantly increased by pECLA (p(a)O(2)/F(I)O(2)=103+/-56 mmHg 2 h after begin) and carbon dioxide removal was markedly enhanced in 25 out of 30 patients (87%) allowing a lung protective ventilation strategy. The mean duration of pECLA therapy was 6.5 days, 15 patients (50%) died due to ARDS or non-ARDS related reasons. CONCLUSION: pECLA represents a feasable and effective treatment in patients with severe ARDS. Compared with pump-driven systems pECLA is characterised by low costs and reduced personnel requirements. However, mortality remains high in patients suffering from severe ARDS despite newer treatment modalities.
Authors: K Lewandowski; R Rossaint; D Pappert; H Gerlach; K J Slama; H Weidemann; D J Frey; O Hoffmann; U Keske; K J Falke Journal: Intensive Care Med Date: 1997-08 Impact factor: 17.440
Authors: Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245
Authors: W M Zapol; M T Snider; J D Hill; R J Fallat; R H Bartlett; L H Edmunds; A H Morris; E C Peirce; A N Thomas; H J Proctor; P A Drinker; P C Pratt; A Bagniewski; R G Miller Journal: JAMA Date: 1979-11-16 Impact factor: 56.272
Authors: Hakan Korkut Atalan; Bulent Gucyetmez; Mert Dumantepe; Mehmet Berktas; Tarik Bugra Denizalti; İbrahim Arif Tarhan; Azmi Ozler Journal: Intensive Care Med Date: 2015-08-22 Impact factor: 17.440
Authors: Markus Zimmermann; Thomas Bein; Matthias Arlt; Alois Philipp; Leopold Rupprecht; Thomas Mueller; Matthias Lubnow; Bernhard M Graf; Hans J Schlitt Journal: Crit Care Date: 2009-01-30 Impact factor: 9.097